These Were The Ten Worst Performing Small-Cap Stocks In March 2022

Small-cap stocks are companies with a market capitalization between $300 million and $2 billion. Historically, such stocks have performed better than large-cap stocks, especially during financial crises. Though these stocks offer higher returns, they are equally risky as well because of their higher volatility. If a trade goes wrong, investors can lose a significant amount of money by betting on small-cap stocks. To give you an idea of the extent of losses, discussed below are the ten worst performing small-cap stocks in March 2022.

Q4 2021 hedge fund letters, conferences and more

Ten Worst Performing Small-Cap Stocks In March 2022

We have used the March return data of small-cap stocks (from finviz.com) to rank the ten worst performing small-cap stocks in March 2022. Following are the ten worst performing small-cap stocks in March 2022:

10. LiveVox Holding (-37%)

Founded in 2014 and headquartered in San Francisco, this company develops cloud-based contact center platforms for healthcare, financial services, telecom, customer care and other industries. LiveVox HoldingLiveVox Holdings Inc (NASDAQ:LVOX) shares are down almost 39% YTD and almost 69% in the last one year. Its shares are currently trading around $3.15, while it has a 52-week range of $2.5 and $10.39. As of writing, LiveVox Holding’s market cap was more than $290 million.

9. Blend Labs (-38%)

Founded in 2012 and headquartered in San Francisco, this company offers cloud-based software platform for financial services firms to support banking products. Blend Labs Inc (NYSE:BLND) shares are down almost 37% YTD. Its shares are currently trading around $4.87, while it has a 52-week range of $4.45 and $21.04. As of writing, Blend Labs’ market cap was more than $1.10 billion.

8. Graphite Bio (-39%)

Founded in 2017 and headquartered in South San Francisco, it is a clinical-stage gene editing company that focuses on therapies harnessing targeted gene integration to treat or cure serious diseases. Graphite Bio Inc (NASDAQ:GRPH) shares are down over 64% YTD. Its shares are currently trading around $4.5, while it has a 52-week range of $4.40 and $34. As of writing, Graphite Bio’s market cap was more than $270 million.

7. NeoGenomics (-42%)

Founded in 1998 and headquartered in Fort Myers, Fla., it is a clinical laboratory company that deals in cancer genetics diagnostic testing and pharma services. NeoGenomics, Inc. (NASDAQ:NEO) has two business segments: Clinical Services and Pharma Services. NeoGenomics shares are down over 66% YTD and over 70% in the last one year. Its shares are currently trading around $11.80, while it has a 52-week range of $11.00 and $54.74. As of writing, NeoGenomics’ market cap was more than $1.4 billion.

6. Omega Therapeutics (-43%)

Founded in 2016 and headquartered in Cambridge, Mass., this company develops DNA-sequence-targeting and mRNA-encoded therapeutics and offers its product under the OMEGA platform. Omega Therapeutics Inc (NASDAQ:OMGA) shares are down almost 49% YTD. Its shares are currently trading around $6.12, while it has a 52-week range of $6.01 and $31.41. As of writing, Omega Therapeutics’ market cap was more than $300 million.

5. Nektar Therapeutics (-50%)

Founded in 1990 and headquartered in San Francisco, it is a biopharmaceutical company that develops and discovers medicines in areas of oncology, immunology and virology. Nektar Therapeutics (NASDAQ:NKTR) shares are down almost 58% YTD and over 70% in the last one year. Its shares are currently trading around $5.61, while it has a 52-week range of $3.88 and $20.66. As of writing, Nektar Therapeutics’ market cap was more than $1 billion.

4. Amylyx Pharmaceuticals (-54%)

Founded in 2013 and headquartered in Cambridge, Mass., it is a biopharmaceutical company that offers disease-modifying solutions for neurodegenerative diseases with a focus on streamlined clinical development and drug discovery. Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) shares are up over 7% in the last five days. Its shares are currently trading around $13.30, while it has a 52-week range of $10.49 and $33.41. As of writing, Amylyx Pharmaceuticals’ market cap was more than $740 million.

3. Cepton (-59%)

Founded in 2016 and headquartered in San Jose, Calif., this company develops and commercializes lidar and imaging technologies for automotive and smart infrastructure industries. Cepton Inc (NASDAQ:CPTN) shares are down almost 63% YTD and over 62% in the last one year. Its shares are currently trading around $3.71, while it has a 52-week range of $3.62 and $80.16. As of writing, Cepton’s market cap was more than $590 million.

2. Icosavax (-60%)

Founded in 2017 and headquartered in Seattle, this company develops and commercializes vaccines against infectious diseases, especially vaccines for viral causes of pneumonia in older adults. Icosavax Inc (NASDAQ:ICVX) shares are down almost 67% YTD. Its shares are currently trading around $7.77, while it has a 52-week range of $4 and $49.99. As of writing, Icosavax’s market cap was more than $250 million.

1. Inspirato (-80%)

Founded in 2011 and headquartered in Denver, it is a travel subscription company that offers users access to hand-selected vacation options through a subscription model. Inspirato Inc (NASDAQ:ISPO) shares are down over 19% YTD and almost 18% in the last one year. Its shares are currently trading around $8.17, while it has a 52-week range of $7.70 and $108. As of writing, Inspirato market cap was more than $1 billion.